An All Oral Treatment for Multiple Myeloma? Richard Labotka, MD, hematologist-oncologist at the University of Illinois Hospital talks about the latest results from the TOURMALINE-MM2 study presented at ASH 2020. TOURMALINE-MM2 compared the oral treatment regimen of ixazomib, lenalidomide, and dexamethasone to placebo, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma. Multiple myeloma […]

Read More